BioSpace News Archive

Neuronetics, Inc. today announced its financial and operating results for the second quarter of 2022.

Eton Pharmaceuticals, Inc. (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it will report second quarter 2022 financial results on Thursday, August 11, 2022.

Aprea Therapeutics, Inc. today announced that Oren Gilad Ph.D, President and Chief Executive Officer, will participate in a panel discussion on synthetic lethality at the 2022 Wedbush PacGrow Healthcare Conference on Tuesday, August 9, 2022 at 12:35 p.m. ET.

PDS Biotechnology Corporation today announced that its management will participate in a fireside chat and one-on-one meetings at the BTIG Biotechnology Conference, a hybrid event taking place August 8-9, 2022.

Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, today announced data demonstrating durable lowering of low-density lipoprotein (LDL) cholesterol in non-human primates and the selection of VXX-401 to pursue as its anti-PCSK9 vaccine candidate to treat hypercholesterolemia.

Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, announced that the Company granted non-statutory stock options to new employees as inducement awards outside of the Company’s 2019 Stock Incentive Plan.

Avidity Biosciences, Inc. today announced that it has commenced enrolling patients from the Phase 1/2 MARINA™ study into a Phase 2 open-label extension study (MARINA-OLE™) of AOC 1001 in adults with myotonic dystrophy type 1 (DM1).

In the worldwide effort to control monkeypox, a novel and fast typing method to trace monkeypox virus strains was developed by Dutch company Molecular Biology Systems (MBS) in collaboration with the department of Medical Microbiology & Infectious Disease Prevention of the Amsterdam UMC and researchers of the Danish Rigshospitalet.

Envisagenics, Inc. announced that it was awarded a Small Business Innovation Research Direct to Phase II grant from the National Cancer Institute, part of the National Institutes of Health.

Diadem srl, a company developing the first blood-based test for the early prediction of Alzheimer’s disease (AD), today reported that study data presented at the Alzheimer’s Association International Conference® 2022 (AAIC®) in San Diego.